Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$0.96.

  • TriSalus Life Sciences' EPS (Basic) fell 70000.0% to -$0.96 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.02, marking a year-over-year decrease of 202.02%. This contributed to the annual value of -$1.31 for FY2024, which is 8062.17% up from last year.
  • Per TriSalus Life Sciences' latest filing, its EPS (Basic) stood at -$0.96 for Q3 2025, which was down 70000.0% from -$0.27 recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year EPS (Basic) high stood at $0.09 for Q1 2022, and its period low was -$79.38 during Q4 2022.
  • Over the past 4 years, TriSalus Life Sciences' median EPS (Basic) value was -$0.43 (recorded in 2024), while the average stood at -$9.72.
  • Within the past 5 years, the most significant YoY rise in TriSalus Life Sciences' EPS (Basic) was 9946.05% (2023), while the steepest drop was 4490000.0% (2023).
  • Quarter analysis of 4 years shows TriSalus Life Sciences' EPS (Basic) stood at -$79.38 in 2022, then surged by 98.68% to -$1.05 in 2023, then soared by 59.05% to -$0.43 in 2024, then crashed by 123.29% to -$0.96 in 2025.
  • Its last three reported values are -$0.96 in Q3 2025, -$0.27 for Q2 2025, and -$0.39 during Q1 2025.